Reading Time: 2 minutes

LOS ANGELES–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24APYX&src=ctag” target=”_blank”gt;$APYXlt;/agt; lt;a href=”https://twitter.com/hashtag/CLASSACTION?src=hash” target=”_blank”gt;#CLASSACTIONlt;/agt;–Glancy
Prongay & Murray LLP
(“GPM”) reminds investors of the upcoming June
17, 2019 
deadline to file a lead plaintiff motion in the class
action filed on behalf of Apyx Medical Corporation (“Apyx” or the
“Company”) (NASDAQ: APYX)
investors who purchased securities between August 1, 2018 and
April 1, 2019
, inclusive (the “Class Period”).

If you are a shareholder who suffered a loss, click here to
participate.

If you wish to learn more about this action, or if you have any
questions concerning this announcement or your rights or interests with
respect to these matters, please contact Lesley Portnoy, Esquire, at
310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected],
or visit our website at www.glancylaw.com.

On February 21, 2019, White Diamond Research released a report alleging
that a clinical study on the use of the Company’s J-Plasma for dermal
resurfacing may have missed its endpoints.

On this news, shares of Apyx fell $2.10 per share, or nearly 25%, to
close at $6.40 on February 21, 2019, thereby injuring investors.

Then, on April 1, 2019, Apyx announced that it had withdrawn its 510(k)
application for the use of J-Plasma for dermal resurfacing, citing
concerns raised by the FDA. Apyx revealed that the FDA had questioned
the device’s clinical results, which differed greatly from two of the
investigational centers used in the study, as well as the potential
impact certain protocol deviations. Moreover, Apyx disclosed that the
clinical study did not meet its primary efficacy endpoint.

On this news, shares of Apyx fell $2.49 per share, or over 35%, to close
at $4.46 on April 2, 2019, thereby injuring investors further.

The complaint filed in this class action alleges that throughout the
Class Period, Defendants made false and/or misleading statements, as
well as failed to disclose material adverse facts about the Company’s
business, operations, and prospects. Specifically, Defendants made false
and/or misleading statements and/or failed to disclose: (1) that the
clinical study on the use of J-Plasma for dermal resurfacing had not met
its primary efficacy endpoint; (2) that, as a result, the clinical study
did not support the Company’s application for regulatory clearance; (3)
that, as a result, the Company was unlikely to receive regulatory
approval of J-Plasma for dermal resurfacing; and (4) that, as a result
of the foregoing, Defendants’ positive statements about the Company’s
business, operations, and prospects were materially false and/or
misleading and/or lacked a reasonable basis.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased or otherwise acquired Apyx securities during the Class
Period you may move the Court no later than June 17, 2019 to
request appointment as lead plaintiff in this putative class action
lawsuit. To be a member of the class action you need not take any action
at this time; you may retain counsel of your choice or take no action
and remain an absent member of the class action. If you wish to learn
more about this class action, or if you have any questions concerning
this announcement or your rights or interests with respect to the
pending class action lawsuit, please contact Lesley Portnoy, Esquire, of
GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067
at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected],
or visit our website at www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Lesley Portnoy,
310-201-9150 or 888-773-9224
[email protected]
www.glancylaw.com